Ausdal Financial Partners, Inc. Sorrento Therapeutics, Inc. Transaction History
Ausdal Financial Partners, Inc.
- $897 Million
- Q3 2024
A detailed history of Ausdal Financial Partners, Inc. transactions in Sorrento Therapeutics, Inc. stock. As of the latest transaction made, Ausdal Financial Partners, Inc. holds 10,000 shares of SRNE stock, worth $3,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$3,300% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding SRNE
# of Institutions
13Shares Held
5.48MCall Options Held
0Put Options Held
0-
B. Riley Securities, Inc. Los Angeles, CA5.22MShares$1.72 Million1.01% of portfolio
-
Swisspartners Ltd. Vaduz, N2110KShares$36,3000.12% of portfolio
-
Lattice Capital Management, LLC51.8KShares$17,0940.01% of portfolio
-
Klcm Advisors, Inc.30KShares$9,9000.0% of portfolio
-
Slate Stone Wealth, LLC21.4KShares$7,0720.0% of portfolio
About Sorrento Therapeutics, Inc.
- Ticker SRNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 449,952,000
- Market Cap $148M
- Description
- Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...